Article Details

In an end-of-year surprise, AstraZeneca nabs rare disease stalwart Alexion in $39B buyout. But why?

Retrieved on: 2020-12-12 14:27:53

Tags for this article:

Click the tags to see associated articles and topics

In an end-of-year surprise, AstraZeneca nabs rare disease stalwart Alexion in $39B buyout. But why?. View article details on hiswai:

Excerpt

Investors at Alexion are getting $175 a share — $60 in cash and the rest in company stock — making this a $39 billion buyout. That qualifies as the ...

Article found on: endpts.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up